Over the next 6 months, I’m excited to announce that the Journal of Dermatological Treatment is calling for all new papers on Psoriasis Treatment to be submitted. The plan is to publish a collection of the highest quality, cutting-edge manuscripts on this important topic. All manuscripts submitted under this special banner will undergo rigorous peer-review as part of the Journal’s standard editorial process. A key bonus feature is that all accepted articles will have gold open access to all interested readers, which can result in more downloads, higher citations, increased visibility, and a broader overall impact of the published material.
Why focus on Psoriasis Treatment? The evolution of treatments for psoriasis over the past 20 years have been revolutionary for improving the lives of individuals with psoriasis. During this time, numerous new therapies (biologics, orals, and topicals) have been approved for psoriasis. Yes, there is already a plethora of published material on mechanisms of action, efficacy, and safety of these new therapies. A constant flow of new literature on these medications, however, continues to challenge and deepen our understanding of how best to use which drug for which patient, and under what circumstance. Thus, with this special collection of manuscripts, we hope to highlight the most interesting and most practical new information on how to treat psoriasis, which we hope will ultimately improve the care of our patients with this impactful disease.
What types of Psoriasis Treatment papers are we hoping to publish? Data derived from large, controlled, clinical trials is always welcome. Both primary results as well as secondary analyses of trial data would be of high value. Data emerging from real-world settings, especially from large databases, is also of particular current interest to the field; these data sometimes offer surprising findings that provide a twist on more traditional phase 3 clinical trial data. Lastly, new findings that add insight into mechanisms of action would also be of high interest to the Journal. Thank you for considering submitting your latest article on Psoriasis Treatment to this special collection at the Journal of Dermatological Treatment. I eagerly look forward to working on this exciting project, learning from my colleagues, and applying newfound knowledge to help my patients.
Dr. Blauvelt has served as a speaker (received honoraria) for AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Regeneron, and Sanofi, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Lipidio, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, and Ventyx.
Please contact Autumn Zellers at [email protected] with any queries regarding this Article Collection.
